Fellow

Fellow (Fellow Health, Inc.) is a high-complexity mail-in semen analysis laboratory in the United States. The company describes itself as the largest dedicated semen analysis facility in the U.S., with a CLIA-certified diagnostics lab and a mail-in collection process that is clinically validated to account for semen degradation over time, which the company states makes it the only mail-in test proven to match the accuracy of a traditional analysis performed within one hour of collection. Results are returned in under two business days from the time a specimen reaches the laboratory.

The product line consists of three consumer-purchasable tests: a post-vasectomy test to confirm the absence of sperm in semen ($149), a full semen analysis for fertility assessment ($199), and a semen analysis bundled with sperm cryopreservation ($199 plus $240 per year of storage). Shipping in both directions is included in the listed prices. Fellow Semen Analysis is also covered by several fertility benefits providers.

Beyond routine analysis, Fellow is developing seminal-fluid-based diagnostics. The company reports research showing that seminal plasma is rich in cell-free DNA from somatic cells, with potential as a liquid biopsy, and that biomarkers in seminal fluid can distinguish clinically significant prostate cancer (Grade Group 2+) from indolent cancer or no cancer.

Founding story

Fellow was founded in 2018 with the stated goal of making semen analysis accessible, comfortable and easy to understand, addressing the reluctance of patients to produce a semen sample in a clinical setting. Its clinical validation was published in Fertility & Sterility in 2021, after which the company began offering what it describes as the only diagnostic-grade mail-in semen analysis on the market.

Business model

Fellow operates its own high-complexity clinical laboratory and sells mail-in diagnostic test kits both directly to patients and through partnerships with urology, fertility and OBGYN practices. Clinics use Fellow to improve lab economics, reduce risk, expand testing access and drive patient conversion to treatment.

Revenue comes from per-test fees for mail-in kits sold direct to consumers ($199 semen analysis, $149 vasectomy test) and recurring annual sperm cryopreservation storage fees ($240/year), alongside testing ordered through partner clinics; the semen analysis is also covered by certain fertility benefits providers.

Traction

Approximately 300,000 tests performed to date (the About page cites more than 225,000 samples analyzed), more than 3,000 clinical partners, a 4.6/5 customer rating across 15,000 reviews, 93% patient satisfaction, 82% compliance with post-vasectomy testing, and 65+ published or presented studies.

Latest developments

Announcements posted to the company site include a partnership with Sunfish to increase access to fertility treatment (July 2026), statewide New York expansion after conditional approval (June 2026), five studies presented at the AUA 2026 Annual Meeting drawing on its network of more than 3,000 practices (May 2026), a partnership with The Y Factor (April 2026), and the appointment of Paul Kappelman as Independent Chairman of the Board (February 2026).